SONNET BIOTHERAPEUTICS HOLDI(NASDAQ:SONN) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 0 out of 10 to SONN. SONN was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of SONN have multiple concerns. SONN is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

SONN had negative earnings in the past year.

In the past year SONN has reported a negative cash flow from operations.

SONN had negative earnings in each of the past 5 years.

SONN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of SONN (-268.39%) is worse than 93.98% of its industry peers.

		Industry Rank	Sector Rank
ROA	-268.39%
ROE	N/A
ROIC	N/A

ROA(3y)-375.01%

ROA(5y)-253.56%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SONN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SONN does not have a ROIC to compare to the WACC, probably because it is not profitable.

SONN has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, SONN has more shares outstanding

SONN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

SONN has an Altman-Z score of -73.18. This is a bad value and indicates that SONN is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -73.18, SONN is not doing good in the industry: 96.28% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-73.18

ROIC/WACCN/A

WACC11.11%

2.3 Liquidity

SONN has a Current Ratio of 0.66. This is a bad value and indicates that SONN is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 0.66, SONN is doing worse than 92.21% of the companies in the same industry.

SONN has a Quick Ratio of 0.66. This is a bad value and indicates that SONN is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 0.66, SONN is doing worse than 92.21% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	0.66
Quick Ratio	0.66

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.70% over the past year.

SONN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -88.15%.

SONN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -77.27% yearly.

EPS 1Y (TTM)64.7%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-59%

Revenue 1Y (TTM)-88.15%

Revenue growth 3Y-66.14%

Revenue growth 5Y-77.27%

Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-16.15%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SONN. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SONN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SONN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SONNET BIOTHERAPEUTICS HOLDI

NASDAQ:SONN (1/22/2025, 2:33:07 PM)

1.65

+0.11 (+7.14%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)12-12 2024-12-12/amc

Earnings (Next)02-12 2025-02-12

Inst Owners13.58%

Inst Owner Change7.22%

Ins Owners5.49%

Ins Owner Change0%

Market Cap4.97M

Analysts82.86

Price Target20.4 (1136.36%)

Short Float %2.11%

Short Ratio0.04

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-91.67%

PT rev (3m)8.11%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-700%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	266.59
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-10.76

EYN/A

EPS(NY)-15.26

Fwd EYN/A

FCF(TTM)-2.86

FCFYN/A

OCF(TTM)-2.86

OCFYN/A

SpS0.01

BVpS-0.16

TBVpS-0.16

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-268.39%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-375.01%

ROA(5y)-253.56%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	93.46%
Cap/Sales	64.41%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.66
Quick Ratio	0.66
Altman-Z	-73.18

F-Score2

WACC11.11%

ROIC/WACCN/A

Cap/Depr(3y)4180.96%

Cap/Depr(5y)2513.68%

Cap/Sales(3y)207.14%

Cap/Sales(5y)124.6%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)64.7%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-59%

EPS Next Y-16.15%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-88.15%

Revenue growth 3Y-66.14%

Revenue growth 5Y-77.27%

Sales Q2Q%-100%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y36.94%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-468%

EBIT Next 3Y-90.14%

EBIT Next 5Y-41.82%

FCF growth 1Y60.43%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y59.67%

OCF growth 3YN/A

OCF growth 5YN/A

SONNET BIOTHERAPEUTICS HOLDI (SONN) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens